Triazines - Therapeutic use
Research News and Information

Tuesday, November 24, 2009

Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III.

30 Aug 2009 BACKGROUND: We report the case of a 16-year-old male with Mucopolysaccharidosis III type A (Sanfilippo syndrome) who was commenced on risperidone for behaviour management. He rapidly developed extrapyramidal symptoms that have not resolved. METHOD: ... Read more...

A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder.

30 Aug 2009 The objective of this study was to evaluate the effectiveness of lamotrigine in reducing affective instability in borderline personality disorder (BPD). We conducted a 12-week, double-blind, placebo-controlled study of 28 patients who met Revised ... Read more...

Rational polytherapy.

30 Aug 2009 Monotherapy has been considered the gold standard for drug treatment of epilepsy. However, there is renewed interest in polytherapy because of the advent of new drugs with fewer drug interactions and novel mechanisms of action, and the realization ... Read more...

Latest indexed articles for 'Triazines - Therapeutic use'

These are the very latest articles for this heading:

• Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III. 30 Aug 2009
• A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. 30 Aug 2009
• Rational polytherapy. 30 Aug 2009
• Use of a new antiepileptic drug or an old one as first drug for treatment of absence epilepsy. 30 Aug 2009
• The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? 30 Aug 2009
• Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. 9 Aug 2009
• The failure to know what isn't known: negative publication bias with lamotrigine and a glimpse inside peer review. 30 Jul 2009
• Study of the comparative efficacy of toltrazuril and diclazuril against ovine coccidiosis in housed lambs. 30 Jul 2009
• End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. 27 Jul 2009
• Ring chromosome 20 syndrome: a link between epilepsy onset and neuropsychological impairment in three children. 30 Jun 2009
• Vardenafil reduces testicular damage following ischemia/reperfusion injury in rats. 29 Jun 2009
• [The role of the neuromodulators in the preventive treatment of migraine] 29 Jun 2009
• Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. 29 Jun 2009
• Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. 20 Jun 2009
• Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial. 16 Jun 2009
• Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability. 30 May 2009
• A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. 30 May 2009
• Sexual functions of men with obstructive sleep apnoea syndrome and hypogonadism may improve upon testosterone administration: a pilot study. 30 May 2009
• Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study. 30 May 2009
• Synthesis, antitumor evaluation, molecular modeling and quantitative structure-activity relationship (QSAR) of some novel arylazopyrazolodiazine and triazine analogs. 27 May 2009

See a longer list of these articles.

Technical information about 'Triazines'

Definition: Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES.

Registry Number: 0

Descriptor UI: D014227

Alternative terms: Triazines; Benzotriazines;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D03.383.931;

Technical Notes: do not confuse with TRIAZENES